Merrill Downgrades IDEC to 'Neutral'

Analyst Eric Ende says he's less certain about the near-term growth potential of the company's cancer drug, Zevalin

Merrill Lynch downgraded IDEC Pharmaceuticals (IDPH ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.